In response to the limitations of broad immunomodulators like IVIG, more targeted complement therapies have emerged, such as the monoclonal antibody eculizumab, which targets C5 and has been proven effective in conditions like atypical hemolytic uremic syndrome and paroxysmal nocturnal hemoglobinuria (41, 42). The gene discussed is C5; the disease is atypical hemolytic-uremic syndrome.